Table 2.

Acute effect of compounds 3c, 3e, and 7c on blood glucose levels in STZ-diabetics mice.

Test samples	Blood glucose concentration (mM)
	Dose (per os) mg/kg of bw	0 h	1.5 h	3 h	5 h	7 h	9 h
Control (vehicle)	–	20.3 ± 10.1	19.0 ± 5.6 (–6.16)	18.2 ± 5.2 (–10.36)	16.4 ± 6.4 (–19.00)	11.5 ± 5.5 (–43.17)	11.5 ± 6.4 (–43.17)
Glibenclamide	10	20.2 ± 5.4	11.6 ± 4.9 (–42.63)	7.6 ± 3.9* (–62.32)	6.1 ± 3.6* (–69.58)	5.7 ± 3.6* (–71.84)	5.6 ± 3.6* (–72.11)
Pterostilbene	40	17.2 ± 7.0	12.1 ± 6.4 (–29.91)	10.2 ± 6.2* (–40.89)	8.4 ± 5.6* (–51.42)	7.7 ± 5.3* (–55.36)	6.9 ± 4.3* (–59.82)
Resveratrol	40	20.0 ± 2.6	16.3 ± 2.9 (–18.42)	14.0 ± 2.0 (–29.83)	12.4 ± 2.1 (–38.08)	11.2 ± 1.8 (–44.25)	10.7 ± 1.4* (–46.33)
3c	10	22.6 ± 7.0	18.1 ± 7.3 (–20.13)	17.0 ± 6.6 (–24.78)	16.8 ± 6.1 (–25.66)	15.7 ± 4.3 (–30.53)	13.2 ± 3.5 (–41.59)
3c	40	21.7 ± 5.7	17.2 ± 5.6 (–20.74)	16.3 ± 7.5 (–25.04)	15.7 ± 6.4 (–27.57)	14.3 ± 9.6 (–34.02)	9.9 ± 4.6* (–54.30)
3c	100	18.6 ± 1.9	15.9 ± 3.6 (–14.34)	15.2 ± 3.0 (–18.28)	15.1 ± 3.7 (–19.00)	13.4 ± 4.7 (–28.23)	11.1 ± 3.0 (–40.32)
3e	10	21.8 ± 6.3	18.8 ± 5.2 (–13.84)	17.8 ± 4.8 (–18.35)	18.6 ± 7.3 (–14.53)	15.6 ± 6.0 (–28.59)	11.5 ± 4.4* (–47.48)
3e	40	20.8 ± 7.6	16.9 ± 5.6 (–18.67)	16.5 ± 9.1 (–20.83)	15.0 ± 8.7 (–28.04)	13.3 ± 9.4 (–36.22)	11.0 ± 8.0 (–47.20)
3e	100	22.5 ± 5.6	15.7 ± 7.7 (–30.37)	16.0 ± 6.8 (–29.04)	15.4 ± 9.6 (–31.78)	12.9 ± 6.4 (–42.81)	10.9 ± 4.5 (–51.48)
7c	10	22.0 ± 5.2	17.0 ± 7.4 (–22.65)	16.9 ± 10.6 (–23.18)	16.1 ± 7.7 (–26.82)	15.7 ± 8.3 (–28.56)	13.3 ± 5.7 (–39.70)
7c	40	20.1 ± 1.9	13.2 ± 2.8 (–34.33)	11.0 ± 3.6* (–45.11)	8.7 ± 2.5* (–56.80)	8.2 ± 1.8* (–59.37)	7.1 ± 1.2* (–64.76)
7c	100	20.2 ± 2.0	13.7 ± 4.0 (–32.43)	11.1 ± 3.0* (–44.88)	9.9 ± 2.5* (–50.83)	8.2 ± 1.9* (–59.49)	6.9 ± 1.4* (–66.01)

Each value is the mean ± SEM for six mice in each group.

^*p < .05 significantly different ANOVA followed by Dunnett’s t-test for comparison with respect to initial levels in each group.

% Variation of glycaemia is in parentheses.